BioSpace News Archive

Protagonist Therapeutics announced that management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera, which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress.

Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial

-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks --

Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), today announced that the company is participating in BIO Digital 2021. The conference is taking place June 14-18, 2021 .

As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data Demonstrates a 44% Best Overall Response for the HEPZATO Arm Versus 17% for the Best Alternative Care Arm Company Q&A Webinar Today at 8:30am ET

Ginkgo Bioworks, Inc. (“Ginkgo”) today announced the signing of a program in a partnership with the Sumitomo Chemical Co., Ltd . (“Sumitomo Chemical”), one of Japan’s leading chemical companies. Ginkgo is building the leading horizontal platform for cell programming, to serve customers across industries seeking to develop better products.

Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders, today announced that Brian Denomme, Co-Founder, previously Reven’s Chief Operating Officer will be stepping into a full-time role as the company’s President.

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Jill Howe as Chief Financial Officer. Ms. Howe brings proven capabilities in private and public financial management, and will oversee all aspects of DTx’s finances.

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for a conditional marketing approval (CMA) for its COVID-19 vaccine in adolescents with the European Medicines Agency (EMA).

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021, at 10:30 a.m. ET.